Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

Detection of developmental toxicity of the anti-COVID-19 drug molnupiravir using gastruloid-based in vitro assays

Huntsman et al., Toxicological Sciences, doi:10.1093/toxsci/kfaf093, Jul 2025
https://c19early.org/huntsman2.html
In Vitro study showing developmental toxicity with N4‑hydroxycytidine (NHC), the active metabolite of molnupiravir, in mouse and human gastruloid models .  Authors exposed P19C5 mouse embryonic‑stem‑cell gastruloids to 20 µM NHC, which severely impeded axial elongation and disrupted developmental gene programs. Human embryonic‑stem‑cell gastruloids manifested aggregate‑size reduction at 10 µM and significant transcriptional changes from 2.5 µM. All toxic concentrations overlap the ~10.8 µM plasma Cmax reached in patients at the authorized molnupiravir dose.  By showing teratogenic signals previously seen in animal studies while eliminating live‑animal use, the gastruloid assay shows value as a rapid, human‑relevant screen for antiviral developmental toxicity.
Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-15. Multiple analyses have identified variants potentially created by molnupiravir16-20.
Huntsman et al., 22 Jul 2025, peer-reviewed, 2 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
DOI record: { "DOI": "10.1093/toxsci/kfaf093", "ISSN": [ "1096-6080", "1096-0929" ], "URL": "https://doi.org/10.1093/toxsci/kfaf093", "abstract": "<jats:title>Abstract</jats:title>\n <jats:p>In pharmaceutical drug development, animal tests are traditionally required to conduct comprehensive toxicity assessments before initiating human clinical trials. However, animal tests are time-consuming and can hinder the rapid development of drugs needed to combat urgent health crises, such as the COVID-19 pandemic. Therefore, faster non-animal alternatives are critical to accelerating preclinical toxicity assessments. Molnupiravir, an antiviral medication authorized for emergency use to treat COVID-19, is an oral pro-drug that is metabolized into its active form, N4-hydroxycytidine (NHC). The developmental toxicity of molnupiravir was initially identified in preclinical animal studies. The present study aims to determine whether in vitro assays using gastruloids–three-dimensional aggregates of pluripotent stem cells that mimic axial elongation morphogenesis of early embryos–can effectively detect the developmental toxicity of molnupiravir in a clinically relevant context. In our experiments, NHC at 20 μM significantly impaired the morphological progression and altered the gene expression profiles in gastruloids derived from mouse P19C5 stem cells. Similarly, in a human embryonic stem cell-based morphogenesis model, NHC reduced the aggregate size at 10 μM and induced significant gene expression changes at concentrations as low as 2.5 μM. Notably, these NHC concentrations are comparable to the plasma levels observed in humans (approximately 10.8 μM) following administration of the clinically recommended dose of molnupiravir. These findings demonstrate that gastruloid-based assays can reliably detect the developmental toxicity of NHC at clinically relevant concentrations, supporting their utility as non-animal tools for expediting preclinical developmental toxicity assessments.</jats:p>", "article-number": "kfaf093", "author": [ { "affiliation": [ { "name": "University of Hawaii John A. Burns School of Medicine Yanagimachi Institute for Biogenesis Research, Department of Anatomy, Biochemistry and Physiology, , Honolulu, HI, 96813,", "place": [ "USA" ] } ], "family": "Huntsman", "given": "Margaret Carrell", "sequence": "first" }, { "ORCID": "https://orcid.org/0000-0001-5720-5806", "affiliation": [ { "name": "University of Hawaii John A. Burns School of Medicine Yanagimachi Institute for Biogenesis Research, Department of Anatomy, Biochemistry and Physiology, , Honolulu, HI, 96813,", "place": [ "USA" ] } ], "authenticated-orcid": false, "family": "Marikawa", "given": "Yusuke", "sequence": "additional" } ], "container-title": [ "Toxicological Sciences" ], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2025, 7, 19 ] ], "date-time": "2025-07-19T11:56:20Z", "timestamp": 1752926180000 }, "deposited": { "date-parts": [ [ 2025, 7, 22 ] ], "date-time": "2025-07-22T04:24:34Z", "timestamp": 1753158274000 }, "indexed": { "date-parts": [ [ 2025, 7, 22 ] ], "date-time": "2025-07-22T04:40:07Z", "timestamp": 1753159207059, "version": "3.41.2" }, "is-referenced-by-count": 0, "issn-type": [ { "type": "print", "value": "1096-6080" }, { "type": "electronic", "value": "1096-0929" } ], "issued": { "date-parts": [ [ 2025, 7, 22 ] ] }, "language": "en", "license": [ { "URL": "https://academic.oup.com/pages/standard-publication-reuse-rights", "content-version": "am", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 7, 22 ] ], "date-time": "2025-07-22T00:00:00Z", "timestamp": 1753142400000 } } ], "link": [ { "URL": "https://academic.oup.com/toxsci/advance-article-pdf/doi/10.1093/toxsci/kfaf093/63814434/kfaf093.pdf", "content-type": "application/pdf", "content-version": "am", "intended-application": "syndication" }, { "URL": "https://academic.oup.com/toxsci/advance-article-pdf/doi/10.1093/toxsci/kfaf093/63814434/kfaf093.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "286", "original-title": [], "prefix": "10.1093", "published": { "date-parts": [ [ 2025, 7, 22 ] ] }, "published-online": { "date-parts": [ [ 2025, 7, 22 ] ] }, "publisher": "Oxford University Press (OUP)", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "https://academic.oup.com/toxsci/advance-article/doi/10.1093/toxsci/kfaf093/8210082" } }, "score": 1, "short-container-title": [], "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": [ "Detection of developmental toxicity of the anti-COVID-19 drug molnupiravir using gastruloid-based in vitro assays" ], "type": "journal-article" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit